Artivion, Inc. (NYSE:AORT – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $39.00.
Several research firms have recently issued reports on AORT. Jefferies Financial Group started coverage on shares of Artivion in a research note on Tuesday, October 20th. They set a “buy” rating and a $31.00 price target for the company. Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Citizens Jmp reduced their price objective on Artivion from $48.00 to $42.00 and set a “market outperform” rating for the company in a report on Friday, November 6th. Needham & Company LLC restated a “buy” rating and set a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Finally, Canaccord Genuity Group dropped their price objective on Artivion from $40.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, November 6th.
Read Our Latest Research Report on Artivion
Insider Buying and Selling at Artivion
In other Artivion news, CEO James P. Mackin sold 70,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the transaction, the chief executive officer owned 877,275 shares in the company, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Andrew M. Green sold 11,480 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $24.97, for a total value of $286,655.60. Following the completion of the sale, the senior vice president owned 40,160 shares in the company, valued at $1,002,795.20. The trade was a 22.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 89,483 shares of company stock worth $2,529,531. 6.30% of the stock is owned by insiders.
Institutional Investors Weigh In On Artivion
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. grew its position in shares of Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after acquiring an additional 399 shares during the period. Amundi increased its holdings in Artivion by 7.5% in the 1st quarter. Amundi now owns 7,186 shares of the company’s stock valued at $263,000 after purchasing an additional 501 shares during the last quarter. Versant Capital Management Inc lifted its stake in Artivion by 38.0% during the 3rd quarter. Versant Capital Management Inc now owns 2,119 shares of the company’s stock worth $48,000 after acquiring an additional 584 shares in the last quarter. Arizona State Retirement System lifted its holdings in Artivion by 6.2% during the 2nd quarter. Arizona State Retirement System now owns 11,709 shares of the company’s stock worth $263,000 after buying an additional 684 shares during the last quarter. Finally, Cetera Investment Advisers lifted its stake in Artivion by 10.8% in the first quarter. Cetera Investment Advisers now owns 9,817 shares of the company’s stock valued at $359,000 after buying an additional 958 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.
Artivion Stock Down 1.5%
AORT traded down $0.29 during trading on Friday, reaching $19.11. 557,999 shares of the stock were exchanged, compared to its average volume of 804,864. The company has a debt-to-equity ratio of 0.82, a quick ratio of 3.02 and a current ratio of 4.42. Artivion has a twelve month low of $18.95 and a twelve month high of $48.25. The stock’s 50 day moving average price is $22.89 and its two-hundred day moving average price is $28.40. The stock has a market cap of $932.47 million, a P/E ratio of -53.09 and a beta of 1.31.
Artivion (NYSE:AORT – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.14. The business had revenue of $123.79 million during the quarter, compared to the consensus estimate of $120.97 million. Artivion had a positive return on equity of 5.12% and a negative net margin of 3.65%.
Artivion Company Profile
Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.
Featured Articles
- Five stocks we like better than Artivion
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
